// App-Quantinova.ai

108 : Antitumor activity and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Alexander E. Drilon

Principal Investigators

  • D. Ross Camidge

  • Sai-Hong Ignatius Ou

  • Jeffrey William Clark

  • Mark A. Socinski

  • Jared Weiss

  • Gregory J. Riely

  • Maria Winter

  • Sherry C. Wang

  • Katherine Monti

  • Keith D. Wilner

  • Paul K. Paik

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of Colorado Cancer Center, Aurora, CO

  • University of California, Irvine, Fullerton, CA

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • University of Pittsburgh Medical Center, Pittsburgh, PA

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Pfizer Oncology, La Jolla, CA

  • Rho Inc., Chapel Hill, NC

Locations

  • United States

Companies

  • PharmAbcine Inc.

  • Rho, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Crizotinib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT00585195

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved